US10738309B2ExpiredUtilityA1

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

89
Assignee: NOGRA PHARMA LTDPriority: Apr 2, 2003Filed: Mar 22, 2018Granted: Aug 11, 2020
Est. expiryApr 2, 2023(expired)· nominal 20-yr term from priority
Inventors:Giovanni Monteleone
C12N 15/113C07H 21/00A61P 43/00C12N 2310/315A61P 29/00C12N 2310/3521C12N 2310/321A61P 1/04A61P 1/00A61K 48/00C12N 2320/30C12N 15/1136C12N 2310/344C12N 2310/314C12N 2310/334A61K 38/00C12N 2310/11C12N 2310/3125C12N 2310/3341
89
PatentIndex Score
1
Cited by
232
References
3
Claims

Abstract

The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. An antisense oligonucleotide against Smad7 consisting of SEQ ID NO: 11 (5′-XGAACATGACCTCXGCAC-3′), wherein X is 5-methyl-2′-deoxycytidine 5′-monophosphate. 
     
     
       2. A method of treating ulcerative colitis, the method comprising administering to a patient in need thereof an effective amount of the antisense oligonucleotide of  claim 1 . 
     
     
       3. A method of treating inflammatory bowel disease, the method comprising administering to a patient in need thereof an effective amount of the antisense oligonucleotide of  claim 1 .

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.